UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 17, 2010

NEUROMETRIX, INC.

(Exact name of registrant as specified in charter)

(781) 890-9989
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

On December 17, 2010, NeuroMetrix, Inc. issued a press release announcing that Nancy E. Katz was appointed to the Company’s Board of Directors. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01  Financial Statements and Exhibits.

(d)  Exhibits.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3

EXHIBIT INDEX

4

Exhibit 99.1

NeuroMetrix Names Nancy E. Katz to Board of Directors

Waltham, Mass — (Business Wire) — December 17, 2010 — NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Nancy E. Katz was appointed to the Company’s Board of Directors.

Ms. Katz is a marketing innovator focused on diabetes care and with over twenty years of experience in the healthcare industry. Most recently Nancy was Senior Vice President, Bayer Diabetes Care — North America where she led a turnaround of this $1.2B business. Previously, she was President and Chief Executive Officer of Calypte Biomedical Corporation, a manufacturer of HIV diagnostics, President of Zila Pharmaceutical, Inc, a manufacturer of oral care products, and held senior marketing positions with the Lifescan division of Johnson & Johnson (blood glucose diabetes products), Schering-Plough Healthcare Products, and with American Home Products. She has served on the Boards of Directors of Neoprobe Corporation, Calypte Biomedical Corporation, LXN Corporation and Pepgen Corporation.

“We are very pleased to welcome Nancy to the Board,” said Shai N. Gozani M.D., PhD., President and Chief Executive Officer of NeuroMetrix.  “Her perspective on diabetes care and experience marketing into the diabetes sector is very relevant as we work toward a successful 2011 launch of NC-stat-SL, our rapid, point-of-care test for diabetic neuropathy.”

“I look forward to contributing to NeuroMetrix at this important juncture,” said Nancy E. Katz. “NeuroMetrix is developing a novel solution to an unmet medical need in a crucial area of diabetic care: the early identification and monitoring of diabetic neuropathy, which is among the most common long term complications of diabetes. The NC-stat SL has impressed me as an elegant product which will promote earlier detection and thereby intervention than might otherwise occur under current practice.”

About NeuroMetrix

NeuroMetrix is a science-based health care company transforming patient care through neurotechnology. We develop and market innovative products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders such as those associated with diabetes, carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis.  For more information, visit http://www.neurometrix.com.

SOURCE: NeuroMetrix, Inc.

NeuroMetrix, Inc.
Thomas T. Higgins,  CFO
neurometrix.ir@neurometrix.com

Ph 781-314-2761